GSK sees more value in licensing than AIDS patent pool
09 March 2010
Anju Ghangurde
GlaxoSmithKline, which has yet to decide on whether or not to participate in
UNITAID's AIDS medicines patent pool, sees more value in its own licensing approach for HIV/AIDS drugs at present.
GSK chief executive Andrew Witty, who was in India to dedicate GSK's new albendazole production line...
Please Login to read the full article.
09 March 2010
Anju Ghangurde
GSK chief executive Andrew Witty, who was in India to dedicate GSK's new albendazole production line...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Big pharma abandoning HIV discounts in middle-income countries, MSF claims
- US Capitol Capsule: Could another biosimilars fight be a brewin'?
- UNITAID set to 'transition' out of CHAI projects
- US Capitol Capsule: Health reform extends Medicare solvency, but programme to go bust by 2024
FEATURES
- Merck BioVentures: where biosimilars make a difference
- DKSH highlights one-stop benefits as it builds Asia market expansion services
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
